Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side effect of Novo Nordisk's popular treatments Ozempic and Wegovy, it said on ...

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

As a dual agonist, it could be more effective than Novo Nordisk A/S (NYSE: NVO) Wegovy or Ozempic for weight loss ... PFE), and Structure Therapeutics Inc. (NASDAQ: GPCR). Pemvidutide is a peptide ...

Novo Nordisk, which manufactures Ozempic, Wegovy and Saxenda ... “This loss of overall structure can impact how dentures or veneers fit, leading to long-term functional and cosmetic dental ...

Novo Nordisk is accused in a suit of failing ... blood supply or ischemia to the optic nerve, the suit alleges. Ozempic, whose chemical name is semaglutide, is part of a class of drugs called ...